GLOW Blend: Copper-Peptide Skin Remodeling Plus Tissue Repair
A copper-peptide-forward single-vial blend pairing GHK-Cu's skin remodeling with BPC-157 and TB-500's tissue-repair support.
What is GLOW Blend?
GLOW pairs GHK-Cu's skin-remodeling and collagen-stimulating effects with BPC-157 and TB-500's tissue-repair support in a single vial — positioned by vendors as the skin-forward counterpart to the more recovery-focused KLOW blend, which adds KPV for gut/anti-inflammatory coverage that GLOW leaves out in favor of a higher relative GHK-Cu dose.
Quick facts
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| Skin & Connective Tissue | Bgrade | anchored on GHK-Cu's human cosmetic literature; no trial of the blend itself |
GLOW Blend Mechanism of Action
A Copper-Peptide-Heavy Recovery Blend
GLOW combines GHK-Cu (dosed as the majority component by mass) with smaller equal doses of BPC-157 and TB-500. GHK-Cu drives collagen, elastin, and angiogenic growth-factor upregulation for skin remodeling; BPC-157 and TB-500 contribute gastroprotective, soft-tissue-repair, and angiogenic support. The higher relative GHK-Cu dose is what gives GLOW its skin-forward positioning compared to KLOW.
Composition
GLOW is most commonly sold as a 70mg vial containing 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500 — a 5:1:1 ratio by mass. This is the same three-peptide combination found in KLOW, minus KPV.
GLOW Blend Dosage and Protocols
Dosing by Total Blend Mass
Reconstitute the 70mg vial with 3.0mL bacteriostatic water for a concentration of about 23.3mg/mL total blend. A typical daily dose is ~2.33mg (2,330mcg) total blend, delivering roughly 1.7mg GHK-Cu, 0.33mg TB-500, and 0.33mg BPC-157 per injection. Cycles commonly run 4–8 weeks.
GLOW Blend Side Effects and Safety
Combined Component Risk Profile
GLOW's side-effect profile reflects the union of its three components' known/theoretical risks — mild injection-site irritation, and the standard caution around active malignancy given BPC-157 and TB-500's angiogenic and cell-migration-promoting mechanisms. No formal combined-product safety trial exists.
GLOW Blend Research Evidence
Individually Studied, Never Combined in a Trial
As with other multi-peptide vendor blends, each of GLOW's three components has its own individual research base, but no clinical trial has tested the 3-peptide combination itself as a product.
Regulatory and Legal Status
GLOW is sold exclusively as a research-grade compound and is not approved for human consumption by the FDA or any equivalent regulatory body. Researchers and users should verify the legal status of GLOW and its individual component peptides in their jurisdiction prior to purchase or use.
GLOW Blend Stacking and Combinations
A Standalone Skin-Forward Blend
GLOW is designed as a standalone skin-and-recovery blend. Some researchers pair it with standalone AHK-Cu for combined hair/skin research coverage, or with GH secretagogue blends for broader systemic recovery support alongside GLOW's skin-focused mechanism.
GLOW Blend Pharmacokinetics
No Unified PK Profile
GLOW's three components have distinct individual pharmacokinetic profiles rather than a single blend-wide half-life — no published pharmacokinetic study exists for the combined product. Reconstituted GLOW should be refrigerated and used within the vendor's recommended window.
Contraindications
- active malignancy
- pregnancy
Frequently asked questions
What is a typical GLOW Blend dose?
Published research protocols report ~2.33 mg total blend, daily. This is the range described in the literature, not a recommendation.
Is GLOW Blend backed by strong evidence?
GLOW Blend carries a REGEN research grade of B. REGEN Research Tier B — observational human data (cohort / case studies).
How is GLOW Blend administered?
Routes reported in the literature: subcutaneous.
Who should avoid GLOW Blend?
Contraindications noted in the literature include active malignancy, pregnancy.